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To the Editor: SARS-CoV-2 infection has spread all over the world. While awaiting a vaccine, we need effective drugs to treat or, even better, prevent coronavirus disease (COVID-19). Two drugs classically used by dermatologists are being examined in the fight against COVID-19: hydroxychloroquine (HCQ), and, very recently, ivermectin. We hypothesize that HCQ and ivermectin may show a consequential and synergistic action if administered simultaneously both for chemoprophylaxis and treatment of COVID-19. HCQ is an anti-malarial drug, analog of chloroquine (CQ), considered as an immunomodulator rather than immunosuppressant. 1 HCQ and CQ inhibit SARS-CoV-2 in vitro with HCQ found to be more potent than chloroquine (CQ). 2 HCQ has shown antiviral effects at both pre-and post-infection stages. 1 clinical isolate in vitro, with a single dose of the drug able to control viral replication within 24-48 h. The authors hypothesized that such results were likely due to the inhibition of IMPα/β1-mediated nuclear import of viral proteins, as shown for other RNA viruses. 4 However, no study with ivermectin in vivo has been already conducted. Basing on all such evidence, we hypothesize that HCQ and ivermectin could act in a consequential and synergistic manner. Indeed, HCQ would behave as a first level barrier by inhibiting the entry of the virus into the host cell, while ivermectin could reduce viral replication if the virus could get in, strengthening HCQ antiviral effects. HCQ is cheap to produce, and safe if monitored properly. Ivermectin seems to be safe and well tolerated with no serious drug-related adverse events. 5 Moreover, such two drugs dot not seem to interact between them. However, no studies, neither in vitro nor in vivo, have been conducted on the combined effect of HCQ and ivermectin on SARS-CoV-2 infection. Ours is only a hypothesis and a suggestion, but if not now, when should researchers share ideas?
